RCS - Hutchmed China Ltd - HUTCHMED to Host Event on Recent Savolitinib Data

What happened

HUTCHMED announced an expert webcast with Citigroup for analysts and investors to discuss recent Phase III savolitinib clinical data in MET-driven non-small cell lung cancer, recently presented at ESMO Congress 2026. The virtual event is scheduled for November 5, 2026.

Confirmed

Global impact / market context

Savolitinib is central to HUTCHMED's future revenue, so updated trial data and regulatory views can shape investor expectations for approval and sales. A Citigroup-hosted event also puts the drug in front of a wider analyst audience.

Analyst inference

HUTCHMED shares trade in Hong Kong, the US and London, so investors are watching trial progress closely. The webcast's timing suggests the company wants to explain the SANOVO China and SAFFRON global studies before regulators make decisions.

Analyst inference

What to watch

1. The webcast will be led by Professor Yi-Long Wu, principal investigator of the SANOVO study, who will share insights on recent clinical data and treatment strategies for MET-driven NSCLC. Confirmed
2. Dr Weiguo Su, CEO currently on leave of absence and Chief Scientific Officer, will join the panel to discuss development progress and the global regulatory outlook for savolitinib. Confirmed
3. Investors will compare how the China SANOVO results and the global SAFFRON study are described, because differences could affect how quickly savolitinib reaches major markets. Analyst inference

Evidence

• Original source link unavailable